Vimarsana
Biggest News Aggregation in the World

Page 31 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

Xenpozyme Approved for Acid Sphingomyelinase Deficiency - Vimarsana News

Xenpozyme Approved for Acid Sphingomyelinase Deficiency

The FDA has approved Xenpozyme (olipudase alfa-rpcp) for non-CNS manifestations of acid sphingomyelinase deficiency in adult and pediatric patients.

Source: empr.com
LDL-C Lowering With Evolocumab Safe, Cuts MACE Risk - Vimarsana News

LDL-C Lowering With Evolocumab Safe, Cuts MACE Risk

Evolocumab significantly reduced LDL-C levels in adults with atherosclerotic cardiovascular disease (ASCVD) for over 8 years.

Source: empr.com
Pemazyre Approved for Certain Myeloid/Lymphoid Neoplasms - Vimarsana News

Pemazyre Approved for Certain Myeloid/Lymphoid Neoplasms

The FDA has approved Pemazyre (pemigatinib) for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Dapagliflozin Beneficial Regardless of Ejection Fraction in HF - Vimarsana News

Dapagliflozin Beneficial Regardless of Ejection Fraction in HF

Dapagliflozin significantly reduced the risk of CV death or worsening of HF in patients with HF and mildly reduced or preserved ejection fraction.

Source: empr.com
Related Topics:
Accessed August
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...